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BACKGROUND: Interleukin-6 (IL-6), a pluripotent cyto-
kine, has traditionally been considered the product
of proinflammatory cells. However, many other cell
types have been shown to produce IL-6. Since in-
testinal inflammation is commonly associated with a
vigorous systemic inflammatory response, we hy-
pothesized that intestinal epithelial and smooth
muscle cells might contribute to that response by
producing IL-6. We therefore studied the capacity of
differentiated human intestinal epithelial and
smooth muscle cell lines to produce IL-6 in response
to various proinflammatory stimuli.
Materials and methods: CCL-241, a human intestinal
epithelial cell line, and HISM, a human intestinal
muscle cell line, were grown to confluency and then
treated for 24 h with various concentrations of
lipopolysaccharide, Clostridium difficile culture ex-
tract containing both toxin A and toxin B, recombi-
nant human tumor necrosis factor-alpha (TNF-a), or
recombinant human interleukin-1 beta (IL-1b). Super-
natants were then collected for IL-6 determination
using an enzyme-linked immunosorbent assay. Cell
numbers were determined using a Coulter counter.
For comparison, parallel studies were performed
using phorbol ester-primed U-937 and THP-1 human
macrophage cell lines.
Results: Both human intestinal epithelial and smooth
muscle cells produced IL-6 under basal conditions. In
HISM cells, but not in CCL-241 cells, IL-6 release was
increased slightly by treatment with C. difficile
culture extract containing both toxin A and toxin B
and with lipopolysaccharide. In both cell lines, IL-6
production was profoundly stimulated by treatment
with IL-1b and less so with TNF-a. Combinations of
high-dose TNF-a and IL-1b may have a slightly
additive, but not synergistic, effect on IL-6 release.
The amount of IL-6 produced by IL-1-stimulated
intestinal cell lines was 70-fold higher than that
produced by stimulated macrophage cell lines.
Conclusions: Both intestinal epithelial and smooth
muscle cells demonstrate the ability to release sig-
nificant amounts of IL-6. The profound response to
IL-1b and TNF-a stimulation by both cell lines sug-
gests that human intestinal parenchymal cells, influ-
enced by paracrine mediators liberated from
proinflammatory cells, might significantly contribute
to the overall systemic inflammatory response by
producing IL-6.
Key words: Interleukein-6, Interleukin-1, Tumor necrosis
factor, Cytokines, Intestine, Epithelium, Smooth muscle,
CCL-241, HISM
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Introduction
Interleukin-6 (IL-6) is a pluripotent cytokine that is
involved in multiple inflammatory processes. IL-6
acts as a pyrogen, mediates B-cell proliferation and
immunogloblin secretion, and is a primary stimulus
for the synthesis of hepatic acute phase proteins.15 It
is also associated with several alterations related to
the metabolic stress of the systemic inflammatory
state, such as the development of cachexia and
anorexia, and stimulation of the hypothalamic/
pituitary/adrenal axis by increasing adrenocortico-
tropin hormone and cortisol release. It is also
involved in regulating the secretion of other hor-
mones, including growth hormone and thyroid-
stimulating hormone.6,7 IL-6 may also have anti-
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inflammatory effects since it downregulates interleu-
kin-1 beta (IL-1b) and tumor necrosis factor-alpha
(TNF-a) secretion, which are known stimulators of IL-
6 production.7
Although IL-6 production has often been attributed
to proinflammatory cells such as macrophages, it has
been demonstrated that IL-6 can be produced by
many other cells, such as neurons, glial cells, adipose
cells, fibroblasts, osteocytes, hepatocytes, endothelial
cells, and a variety of other epithelial cells.616 In fact,
IL-6 was initially identified as interferon N produced
by fibroblasts and as hepatocyte stimulatory factor
produced by a cervical carcinoma cell line.1,8
Intestinal cells may likewise be an important
source of IL-6. IL-6 produced in the intestine may
be of significance not only in the local regulation of
intestinal immunologic and defense functions, but
also could contribute to the development of the
systemic inflammatory response. It has been shown
that IL-6 production by the intestinal mucosa is
upregulated in a number of intestinal disease states,
including ischemia/reperfusion (I/R) injury, chronic
rejection following small bowel transplantation and
inflammatory bowel disease.1720 Mucosal specimens
taken from patients with inflammatory bowel disease
exhibit enhanced IL-6 production,2132 but the cel-
lular origin of IL-6 is unclear. While there is debate, a
few reports have suggested that IL-6 production
comes directly from the intestinal epithelial cells3336
or from smooth muscle cells.3739 To more clearly
document the potential contribution of intestinal
epithelial and smooth muscle cells to local and
systemic IL-6 production, we studied IL-6 release by
pure cultures of these cells. Additionally, since IL-6
release is stimulated by a variety of exogenous
bacterial products as well as endogenous inflamma-
tory mediators,7,10,11 we studied the responses of




CCL-241, a human intestinal epithelial cell line
derived from normal human fetal tissues, and HISM,
a human intestinal smooth muscle cell line isolated
from jejunal muscularis propria of a normal adult
female, were utilized. Two monocytic cell lines, U-
937, a monocyte cell line derived from histiocytic
lymphoma, and THP-1, a monocyte cell line isolated
from acute monocytic leukemia, were activated by
pretreatment for 48 h with 40 and 16 nM of 12-o -
tetradecanoylphorbol-13-acetate (Sigma, St Louis,
MO, USA) to induce attachment and macrophage
differentiation.40,41 CCL-241 and HISM were grown
on 24-well plates in Dulbecco’s modified Eagle’s
medium (Sigma) with 10% fetal bovine serum
(Sigma) and U-937 and THP-1 in RPMI 1640 medium
(Sigma) with 10% fetal bovine serum. Media was
changed (or added for the monocytic cell lines prior
to attachment induced by phorbol esters) every 2/3
days and were split at confluency or subcultured at
1/106 cells/ml as assessed by cell counting using a
hemocytometer. All cells were maintained in a 378C
incubator in an atmosphere of 95% air and 5% CO2.
IL-6 production
At confluency, cultures were treated for 24 h with
culture medium containing various concentrations of
a Clostridium difficile culture extract (TechLab,
Blacksburg, VA, USA), which contains both toxin A
and B, lipopolysaccharide (LPS) (Eschericha coli
0111:B4; Difco Laboratories, Detroit, MI, USA), re-
combinant human IL-1b (R&D Systems, Inc., Minnea-
polis, MN, USA), or recombinant human TNF-a (R&D
Systems, Inc.). Supernatants were removed and
centrifuged at 1000 g/5 min to remove detached
cells and were stored at /808C for subsequent IL-6
determination. Phosphate-buffered saline containing
trypsin was added to detach adherent cells, and the
cells were centrifuged at 1000 g/5 min and resus-
pended in phosphate-buffered saline for determina-
tion of cell numbers using a Coulter counter.
Sandwich enzyme-linked immunosorbent assay
(ELISA) for human IL-6 was performed according to
the manufacturer’s directions. This was based on the
DuoSet ELISA Development System (R&D Systems,
Inc.), which utilizes a mouse anti-human IL-6 capture
antibody, a biotinylated goat anti-human IL-6 detec-
tion antibody, horseradish peroxidase-conjugated
streptavidin, and H2O2/tetramethylbenzidine as the
peroxidase substrate. Samples were read using a dual
wavelength spectrophotometer (450 nm reading, 540
nm correction), and the amount of IL-6 was calcu-
lated using a standard curve prepared with known
amounts of purified recombinant human IL-6. Ac-
cording to the specifications provided by the manu-
facturer, the sensitivity of the assay for IL-6 in culture
supernatants was 0.70 pg/ml. No significant cross-
reactivity or interference was observed with other
cytokines or inhibitors, including leukemia inhibitory
factor and interleukin-11. In repetitive testing, intra-
assay coefficients of variation ranged from 1.7 to 4.4
and inter-assay coefficients of variation ranged from
2.0 to 3.7.
Statistical methods
Measurements represent mean9/standard error of the
mean. The amounts of IL-6 produced under different
conditions were compared within each cell line using
a paired t -test with Bonferroni correction for multiple
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comparisons with control values. The unpaired t -test
was utilized for comparisons between cell lines.
Results
CCL-241 release of IL-6 following treatment with
C. difficile toxin, LPS, IL-1b, and TNF-a
The human intestinal epithelial cell line released
detectable amounts of IL-6 into the culture medium
under basal conditions (Table 1). Neither C. difficile
toxins nor LPS stimulated IL-6 release. Both IL-1b and
TNF-a stimulated IL-6 release in a dose-dependent
manner. TNF-a produced a 10-fold increase in IL-6
release, while IL-1b elicited a 150-fold increase in IL-6
release. Cells stimulated with high concentrations of
both IL-1b and TNF-a produced greater amounts of
IL-6 than those stimulated with either cytokine alone,
although this was not statistically significant (Table
2). However, combinations of IL-1b and TNF-a at
lower concentrations (2.0 U/ml and 1 ng/ml, respec-
tively) elicited a seven-fold increase in IL-6 produc-
tion compared with that produced by either cytokine
alone.
HISM release of IL-6 following treatment with C.
difficile toxin, LPS, IL-1b, and TNF-a
The human intestinal smooth muscle cell released 14-
fold higher amounts of IL-6 under basal conditions
than did the CCL-241 cells (Table 1). C. difficile
toxins and LPS stimulated slight increases in IL-6
release, although these did not reach statistical
significance. As with CCL-241 cells, both TNF-a and
IL-1b stimulated IL-6 release in a dose-dependent
manner. TNF-a increased IL-6 release approximately
four-fold but IL-1b elicited a greater than 10-fold
increase in IL-6 release. Combinations of high-dose
IL-1b and TNF-a also resulted in a slight augmenta-
tion of IL-6 release compared with that of IL-1b alone,
although these were not statistically significant (Table
2). Additionally, combinations of lower concentra-
tions of IL-lb and TNF-a (2.0 U/ml and 1 ng/ml,
respectively) did not give rise to increased IL-6
release compared with that produced by either
cytokine alone.
Macrophage release of IL-6 following treatment
with C. difficile toxin, LPS, IL-1b, and TNF-a
Under basal conditions, U-937 cells released small
amounts of IL-6. However, the amounts of IL-6
produced by THP-1 cells were insufficient for detec-
tion using the ELISA. C. difficile toxins, IL-1b, and
TNF-a elicited no further stimulation of IL-6 in U-937
cells. LPS, however, increased IL-6 production 50-fold
in U-937 cells and stimulated THP-1 cells to produce
detectable levels of IL-6 (Table 2). It is notable that
the maximum amount of IL-6 produced by these
macrophage cell lines was 100-fold less than that
produced by maximally stimulated CCL-241 or HISM
cells.
Table 1. Effects of various stimuli on IL-6 production by CCL-241 cells, and on IL-6 release by HISM cells and by macrophage
cell lines
IL-6 production by CCL-241 cells IL-6 release by HISM cells IL-6 release by macrophage cell
lines
Stimulator IL-6 (pg/1000 cells) IL-6 (pg/1000 cells) U-937 THP-1
None 109/10 1509/60 0.59/0.3 N.D.
CdT (1:2/107) 99/8 1409/70 0.59/0.4 N.D.
CdT (1:2/106) 79/6 1809/85 0.59/0.3 N.D.
CdT (1:2/105) 59/5 1609/80 0.59/0.3 N.D.
CdT (1:2/104) 49/4 2709/170 0.59/0.3 N.D.
CdT (1:2/103) 119/15 5409/490 0.69/0.3 N.D.
LPS (0.001 mg/ml) 109/10 1659/75 29/1 0.19/0.0
LPS (0.01 mg/ml) 89/5 1609/70 69/2* 19/0.2
LPS (0.1 mg/ml) 89/3 1909/90 149/7* 59/1
LPS (1.0 mg/ml) 99/3 2509/160 239/12* 109/4
LPS (10 mg/ml) 109/5 2309/116 249/11* 119/4
IL-1b (0.02 U/ml 109/9 1709/90 0.59/0.3 N.D.
IL-1b (0.2 U/ml)) 209/13* 1909/100 0.59/0.3 N.D.
IL-1b (2.0 U/ml) 4509/150* 2709/125 0.59/0.3 N.D.
IL-1b (20 U/ml) 8109/430* 10609/580* 0.59/0.3 N.D.
IL-1b (200 U/ml) 13009/740* 25009/1100* 0.59/0.3 N.D.
IL-1b (2000 U/ml) 15009/950* 23809/1200* 0.69/0.3 N.D.
TNF-a (0.1 ng/ml) 279/20 2309/104 0.59/0.3 N.D.
TNF-a (1.0 ng/ml) 339/25* 3829/226* 0.59/0.3 N.D.
TNF-a (10 ng/ml) 709/41* 4819/270* 0.59/0.3 N.D.
TNF-a (100 ng/ml) 1069/70* 5609/385* 0.89/0.2 N.D.
n/6 experiments/condition, *pB/0.05 versus control (with Bonferroni correction for multiple comparisons). CdT, C. difficile culture extract
containing both toxin A and toxin B; N.D., not determined.
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Discussion
IL-6 was originally identified on the basis of many
different biologic activities and was variously called
interferon-b2, B-cell stimulatory factor 2, 26 kDa
protein, hybridoma/plasmacytoma growth factor,
hepatocyte stimulating factor, and monocyte granu-
locyte inducer type 2.1 IL-6 and other cytokines that
bind to the cellular IL-6 receptor or the soluble IL-6
receptor have been implicated in the pathogenesis of
a broad spectrum of disease processes, including
Castleman’s Syndrome and multiple myeloma, Kapo-
si’s sarcoma-associated herpes virus-8 infection,
thrombosis in myocardial infarction, myocardial cell
hypertrophy in congestive heart failure, osteoporosis
and other diseases with increased osteoclastic bone
resorption, rheumatoid arthritis, systemic lupus er-
ythematosis, and cancer-related anorexia/cachexia
syndrome.6,7,14,4246
In the gut, IL-6 has been linked to I/R injury,
chronic rejection following small bowel transplanta-
tion, and both Crohn’s disease and ulcerative
colitis.1720 In a rat intestinal I/R model, accumula-
tion of IL-6 mRNA in the mucosa and muscularis
externa was shown to precede immunohistochemical
evidence of cellular I/R injury.17 In rat small intestinal
transplants, in situ hybridization demonstrated the
presence of increased mucosal and muscularis ex-
terna IL-6 mRNA in experimental chronic rejection.18
A number of clinical reports have also suggested a
role of IL-6 in the pathogenesis of inflammatory
bowel disease. Both patients with Crohn’s disease
and with ulcerative colitis have elevated amounts of
IL-6 in the serum,47,48 in circulating and resident
proinflammatory cells,49,50 and in mucosal sam-
ples.21,22 While a number of studies have demon-
strated increases in IL-6 production by mucosal
biopsies, there has been little consensus with regard
to the primary cellular source of IL-6. A few studies
utilizing in situ hybridization for IL-6 mRNA or
measuring IL-6 in Percoll gradient isolated intestinal
epithelial and lamina propria mononuclear cells have
suggested that the primary source of IL-6 is from the
lamina propria mononuclear cells.2430
However, in one of these studies, in situ hybridi-
zation demonstrated greater amounts of IL-6 message
in the mucosa than in the lamina propria.30 Addi-
tionally, a different study using in situ hybridization
demonstrated equally prominent IL-6 expression in
both areas.31 Finally, a study detecting IL-6 protein
using immunohistochemistry/fluorescence demon-
strated that IL-6 was predominantly present in the
enterocytes and colonocytes of patients with inflam-
matory bowel disease.32 Therefore, it remains unclear
whether one or both of these cell types are the most
important contributors to IL-6 production during
intestinal inflammation.
Although normal intestinal epithelial cells have
been shown to express IL-6 receptors and to respond
to IL-6,33 few studies have focused on the production
of IL-6 by pure intestinal epithelial cell lines. Good-
rich and McGee have demonstrated that IL-6 can be
produced by cultured rat intestinal cells,34 and Strong
et al . have shown that IL-6 mRNA is produced by
primary cultures of human intestinal cells.35 How-
ever, Fayyazi et al . stated that IL-6 mRNA was
undetectable in human colonic epithelium.36 There
are also some studies suggesting that intestinal
smooth muscle cells produce IL-6. In the rat intestine,
and in cultured rat intestinal smooth muscle cells, IL-
1b and TNF-a were found to stimulate IL-6 mRNA
and IL-6 production.3739 Possible IL-6 production by
the intestinal smooth muscle cells could therefore
correspond to the findings of significant IL-6 localiza-
tion in the muscularis externa in animal models of I/R
injury and chronic rejection.17,18
In our studies, the representative human cell lines,
CCL-241 and HISM, were potent producers of IL-6
Table 2. Effect of combined stimuli on IL-6 production
CCL-241 cellsa HISM cellsb
Stimulator IL-6 (pg/1000 cells) IL-6 (pg/1000 cells)
None 39/2 1309/50
LPS (10 mg/ml) 39/1 2239/90
IL-1b (2.0 U/ml) 329/14 2509/95
IL-1b (200 U/ml) 8629/357 14009/615
TNF-a (1.0 ng/ml) 339/8 4809/220
TNF-a (100 ng/ml) 1089/54 7009/400
LPS and IL-1b (200 U/ml) 9359/723 13359/550
LPS and TNF-a (100 ng/ml) 1669/102 10009/585
LPS and TNF-a (100 ng/ml) and IL-1b (200 U/ml) 17259/869 24409/1140
TNF-a (1.0 ng/ml) and IL-1b (200 U/ml) 8599/343 25009/990
TNF-a (100 ng/ml) and IL-1b (2.0 U/ml) 3919/188 11009/740
TNF-a (1.0 ng/ml) and IL-1b (2 U/ml) 2219/113* 5259/260
TNF-a (100 ng/ml) and IL-1b (200 U/ml) 12519/511 24709/1070
an/4 experiments/condition, *pB/0.05 versus IL-1b (2.0 U/ml) versus TNF-a (1.0 ng/ml) (with Bonferroni correction for multiple
comparisons).bn/6 experiments/condition, no values reached statistical significance of pB/0.05 versus appropriate control (with Bonferroni
correction for multiple comparisons).
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when stimulated by TNF-a, and particularly by IL-1b.
Our findings correspond to other studies that have
shown these cytokines to be the primary stimulators
of IL-6 production from other cell lines.813 IL-1b and
TNF-a may have had slight additive effects on the
amount of IL-6 production, although this effect was
not dramatic. The failure to demonstrate greater
responses to combinations of these cytokines may
indicate that both agents act through a common final
mechanism to stimulate IL-6 production.
The amount of IL-6 produced by the epithelial and
smooth muscle cells was substantially greater than
that produced by the macrophage cells. In addition,
the stimuli eliciting IL-6 release were quite distinct;
LPS was the most potent stimulator of macrophage
IL-6 release, but it only slightly stimulated IL-6 release
by intestinal smooth muscle cells and had no effect
on intestinal epithelial cells. However, it might be
anticipated that intestinal epithelial cells should not
respond to LPS since these cells might normally be
exposed to luminal endotoxin on a constant basis.
Exposure to C. difficile toxins and LPS did seem to
produce a trend towards increased IL-6 production
by the intestinal smooth muscles cells. This seems
reasonable since these cells would not normally be
exposed to luminal toxins in vivo .
Overall, the findings from these experiments
clearly demonstrate that intestinal epithelial and
smooth muscle cells have the capacity to produce
1L-6. It can be hypothesized that IL-6 production by
these cells plays a role in the local and systemic
inflammatory processes during intestinal diseases. An
initiating factor (such as exposure of the lamina
propria to endotoxin) could stimulate IL-1b and
TNF-a production by the resident macrophages and
other proinflammatory cells in the bowel wall. These
cytokines could then stimulate intestinal epithelial
cells and intestinal smooth muscle cells to produce
IL-6. This IL-6, acting in a paracrine fashion, could
modulate the local immunologic and inflammatory
responses in the bowel wall. In addition, the IL-6
produced could also act in an endocrine fashion to
augment the systemic inflammatory reaction. Thus,
the resident parenchymal and mesenchymal cells of
the bowel through their elaboration of mediators,
such as IL-6, may be of importance in understanding
the pathogenesis of intestinal diseases.
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